Navigation Links
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Date:7/7/2008

g," said Lynn Seely, M.D., chief medical officer of Medivation. "These data are also important because they provide further support for our belief that Dimebon is exerting its benefits through a novel mechanism of action targeting mitochondrial dysfunction, a contributor to the loss of neuronal function in Huntington's disease. Medivation is committed to aggressively advancing development of Dimebon for patients and families devastated by Huntington's disease."

Full results from the Phase 2 study will be submitted for presentation at an upcoming scientific meeting.

About Huntington's Disease

Huntington's disease is a progressive, neurodegenerative disease that affects approximately 30,000 people in the U.S., with an additional 150,000 at risk, qualifying it as an orphan drug indication. It is caused by the death of specific brain cells and is characterized by the gradual development of involuntary muscle movement, progressive deterioration of cognitive processes and memory (dementia) and severe behavioral disturbances. There are currently no drugs approved by the U.S. Food and Drug Administration to treat this uniformly fatal genetic disorder.

About Dimebon

Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. The Company is currently enrolling patients in an international confirmatory Phase 3 clinical trial evaluating the efficacy and safety of Dimebon in patients with mild-to-moderate Alzheimer's disease. Preclinical data generated to date suggest that Dimebon operates through a novel mitochondrial mechanism of action.

Teleconference/Webcast Details

Medivation will host a teleconference at 5:00 p.m. Eastern Daylight Time today. To participate in the live call by telephone, please dial 877-419-6590 from the U.S. or 719-3
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced the ... Global Strategic Business Report" report to their offering. ... Canada , Japan , ... Latin America , and Rest of World. ... through 2020. Also, a seven-year historic analysis is provided for ...
(Date:6/2/2015)... 2, 2015 The North ... the concerned market with analysis and forecast of ... in 2014, and is estimated to reach $632.5 ... from 2014 to 2019. Browse through ... for an analysis of industry trends and segments, ...
(Date:6/2/2015)... , June 2, 2015 BioDelivery Sciences International, ... conditions, the presentation by Dr. Mark A. Sirgo , ... to 2:30 PM Eastern time. Jefferies 2015 Global ... Grand Hyatt, New York City , NY ... be accessed at www.bdsi.com .  For those who are ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 3
... VIVUS, Inc. (NASDAQ: VVUS ) today ... accepted for review the company,s new drug application (NDA) for ... dysfunction (ED). The target date for the FDA to complete ... In previously announced results from the pivotal phase 3 trials, ...
... Sept. 1, 2011 Lung Cancer Alliance ... of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) ... on data from two clinical trials, both of which ... Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma ...
Cached Medicine Technology:VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 2VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 3New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population 2
(Date:6/2/2015)... Jersey (PRWEB) June 02, 2015 The ... BCBSNJ) announced today that its Walking and Wellness Challenge, ... Presented by Acer, has raised another $3,000 for the ... Gulbis undertook the challenge, recording 32,000 steps on her ... Stockton Seaview Hotel & Golf Club in Galloway Township. ...
(Date:6/2/2015)... 02, 2015 “ Radaris ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... they need on a person. , According to Psychology Today, ... goes on to explain that curiosity is a part of ...
(Date:6/2/2015)... On October 1, 2015 the transition to ... , On Monday, June 1st Congressman Kevin ... Ways and Means Committee, and 12 members of the ... Medicaid Services, urging the administration to provide a smooth ... ICD-10 is the newest coding system for healthcare professionals ...
(Date:6/2/2015)... Claflin Medical Equipment , a Rhode Island ... RSI Equipment, Inc ., a New York ... With CME’s recent merger of Hospital Associates ... organizations which specialize in the procurement and delivery of ... forces, they now cover the entire country with three ...
(Date:6/2/2015)... Acara Partners has seen a spike in demand for developing ... is now required by recent Google search algorithm changes. ... new clients in the medical aesthetics vertical, are anxious for ... Google’s new requirements,” commented Fran Acunzo, CEO of Acara Partners. ... non-profits, and the business world.” , Back in late ...
Breaking Medicine News(10 mins):Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:Claflin Medical Equipment (CME) Announces Acquisition of RSI Equipment, Inc. 2Health News:Acara Partners Expands Website and Digital Offerings 2
... National Basketball Association of the US has teamed up with ... kits on HIV/AIDS //to schools in seven provinces of China. ... the kits contain interactive HIV/AIDS learning materials for teachers and ... kit also contains a basketball and other sports equipment to ...
... care services provided to children with special health care ... be below their required need. //In addition, the poorer ... mental health care needs met. These are the two ... Harvard School of Public Health (HSPH) researchers, published in ...
... is generally referred to any factor that affects the physical, ... as we all know, has ramified into various sections of ... ,Although it has been argued that normal levels of ... many. During stress, an important hormone, cortisol, is secreted by ...
... long running disagreement over the funding of the brachytherapy machine ... travel to Christchurch for specialist treatment. ... cervical and other gynecological cancers and was proposed to be ... been ordered because the DHB wants other DHBs to share ...
... According to a study done by Ian Sheerin, lecturer ... of the patients were categorized as avoidable admissions//. The ... could be saved if the condition of the patients ... New Zealand Medical Journal. The largest proportion of avoidable ...
... the effects of alcohol during the drug action week. In ... part of drug action week. ,The role of ... and mental disabilities in children will be stressed during these ... disorders in Kimberley is as high as one in five. ...
Cached Medicine News:Health News:Health Care For Children With Special Needs Compromised 2Health News:Drug Action Week to Highlight Effects of Alcohol 2
IFA for the direct detection of Respiratory Syncytial Virus (RSV)...
BD Directigen RSV Test fast, easy and accurate, its truly STAT. And it will help your laboratory quickly and confidently support critical antiviral therapy recommendations....
Qualitative ELISA for the detection of rotavirus antigen....
Rapid membrane-based immunogold assay for the qualitative detection of rotavirus antigen in human fecal specimens; aids in the diagnosis of acute gastroenteritis caused by rotavirus infection....
Medicine Products: